MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
about
Molecular biology of lung cancer: clinical implicationsPrognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.Lung cancer. 9: Molecular biology of lung cancer: clinical implications.Chromosome instability in human lung cancers: possible underlying mechanisms and potential consequences in the pathogenesis.Image cytometric analysis of p53 and mdm-2 expression in primary and recurrent mucoepidermoid carcinoma of parotid gland: immunohistochemical study.The MDM2 gene amplification databaseGenetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer.Association of MDM2 SNP309, age of onset, and gender in cutaneous melanomaProteomic signatures associated with p53 mutational status in lung adenocarcinoma.Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interactionImmunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluationGenetic changes in squamous cell lung cancer: a reviewMDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology.Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers.Correlation of p53, MDM2 and p14(ARF) protein expression in human esophageal squamous cell carcinoma.mir-660-p53-mir-486 Network: A New Key Regulatory Pathway in Lung TumorigenesisThe Role of MDM2 Amplification and Overexpression in Tumorigenesis.Overexpression of HER-2/neu protein attenuates the oxidative systemic profile in women diagnosed with breast cancer.PKCδ regulates Mdm2 independently of p53 in the apoptotic response to DNA damage.P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese.Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs.MDM2 is overexpressed and regulated by the eukaryotic translation initiation factor 4E (eIF4E) in human squamous cell carcinoma of esophagus.Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung.MDM2 gene amplification in colorectal cancer is associated with disease progression at the primary site, but inversely correlated with distant metastasis.Three new regions on chromosome 17p13.3 distal to p53 with possible tumor suppressor gene involvement in lung cancer.Possible implication of Mdm2 as a prognostic marker in invasive laryngeal carcinoma
P2860
Q24610335-35DCEDD4-4626-4C8A-B220-7DD1AFC7FFE6Q30497419-6E5BB35E-531E-4032-9E87-C7B1D954E770Q33972805-B5DCA87D-0A1E-460E-A70A-AE42A8369DAFQ34152941-5594D500-CF7D-46E7-9F4C-0D9BD3471455Q34400192-14E9DF7C-6940-4688-B79F-3A2D35EEBD49Q34672224-C7E96467-459F-4786-8EF4-91A706D1E73FQ34963574-2C0DB3C3-C35F-4732-806A-DFA598C2F983Q34968358-C0811D84-606B-4C8D-AA3B-2E98E3584A16Q35492010-EFBDD221-3D62-4B70-A55F-4EBE0E4F09B7Q35679203-7A84BF64-7B7A-4C2C-A2F7-72EA0E5B3597Q35770249-53C4643F-CCA3-42E0-969A-CCDA9A38FB06Q36115735-71FC2E7B-BDC2-46F4-BBD4-CC098DA561B2Q36150107-3DBE1E0A-FBC2-4F8B-B634-A109A6B8723FQ36617994-D66BECB3-0341-405B-80EC-31E5005528B3Q36728827-597E8701-F116-4CA3-B457-8C2200190DBDQ37504800-3A815E3B-85D0-4D73-9F2D-231869E9DA70Q37631729-9172EC71-2A6A-43A7-AD52-8A7ED062A70DQ38837916-B1B9353D-284C-40D9-A240-C448E2161FBEQ39061588-FFA2B0E7-7B1F-4A0B-85B6-C2BA9DD67BC9Q39581477-8A00B3AB-5F34-4647-92DF-7D5E5F7035C4Q40864851-7AF98F25-A369-4818-A4FC-E746337F3D10Q43235127-D2DB78F0-CA41-4BD6-A2B4-0E3108C093DFQ43622152-79F0887C-02C0-4217-95F4-3BE0E1AFF0D3Q43966872-CCEC1545-C695-4B32-96CA-D630FACA093BQ46489653-FF1BC371-1539-4177-9274-F814325499BBQ47791315-16F8EC03-E61A-4068-AD72-36F28CE98B65Q48018005-3F41573E-0AD1-4AC5-A487-D9B1EEAA419BQ51743355-7CAC63AE-6D99-4B1C-8A03-0C9F4AAD94DFQ52545817-B2EF72CA-DD9F-4923-AC78-A65951B8500BQ54428508-74742CE6-05A0-43D2-98E6-005E8C294D86Q55006015-1B74D65D-4EE8-47CF-8968-AA5F4F20E797Q58851158-B3810714-CCEF-4EC3-84A3-BDD4E5032663
P2860
MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
MDM2 gene amplification and ex ...... hout p53 protein accumulation.
@ast
MDM2 gene amplification and ex ...... hout p53 protein accumulation.
@en
type
label
MDM2 gene amplification and ex ...... hout p53 protein accumulation.
@ast
MDM2 gene amplification and ex ...... hout p53 protein accumulation.
@en
prefLabel
MDM2 gene amplification and ex ...... hout p53 protein accumulation.
@ast
MDM2 gene amplification and ex ...... hout p53 protein accumulation.
@en
P2093
P2860
P356
P1476
MDM2 gene amplification and ex ...... hout p53 protein accumulation.
@en
P2093
H Yokouchi
I Nishisho
M Higashiyama
S Ishiguro
T Nakayama
P2860
P2888
P304
P356
10.1038/BJC.1997.221
P407
P577
1997-01-01T00:00:00Z